Recurrence Risk For Small HER2-Positive Breast Cancer Reduced By Combined Therapy

Recurrence Risk For Small HER2-Positive Breast Cancer Reduced By Combined Therapy
shutterstock_130569779A new study of adjuvant paclitaxel and trastuzumab combination in patients with stage I breast cancer found an encouraging progression free survival rate of 98.7% and recurrence risk of 2% . The study entitled, “Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer”, was published in The New England Journal of Medicine. In nearly 15-20% of invasive breast cancers there is an overexpression of the human epidermal growth factor receptor type 2 (HER2), which is associated with poorer outcomes. Trastuzumab, a humanized monoclonal antibody that binds HER2, has been found to improve the clinical outcomes for patients with HER2-positive breast cancer. Results from phase 3 randomized trials comprising more than 8,000 patients revealed that when trastuzumab was administered in combination or after chemotherapy, the risk of recurrence was decreased by approximately 50% and overall survival improved. However, these trials included patients with stage II or stage III HER2-positive breast cancers. At the moment, there is no single standard treatment for patients with small, node-negative, human epidermal growth
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.